

## Cyanotic Congenital Heart Disease

<b>Key Document code:</b>	WAHT-TP-095	
<b>Key Documents Owner:</b>	Dr T Dawson	Consultant Paediatrician
<b>Approved by:</b>	Paediatric Quality Improvement meeting	
<b>Date of Approval:</b>	26 <sup>th</sup> March 2021	
<b>Date of review:</b>	26 <sup>th</sup> March 2024	
This is the most current document and should be used until a revised version is in place		

The following guidance is taken from the Partners In Paediatrics (PIP)

Cyanotic congenital heart disease 2018–20

# CYANOTIC CONGENITAL HEART DISEASE

## RECOGNITION AND ASSESSMENT

### Symptoms and signs

- Central cyanosis may be respiratory or cardiac in origin
- Respiratory illness producing cyanosis will usually have signs of respiratory distress (e.g. cough, tachypnoea, recession and added respiratory sounds)
- Cardiac decompensation may occur with a respiratory infection; they may co-exist
- Cyanosis more likely due to cardiac disease if:
  - SpO<sub>2</sub> responds poorly to high flow oxygen (15 L/min) via face mask with reservoir bag
  - marked tachycardia
  - enlarged heart (clinically or on CXR)
  - gallop rhythm/murmur
  - enlarged liver/raised JVP
  - basal crackles
  - absent femoral pulses
  - finger clubbing occurs after a few months (also consider endocarditis)

### Causes of cardiac cyanosis

#### **Significant right-to-left shunt**

- Transposition with inadequate mixing, pulmonary or tricuspid atresia
- Fallot's tetralogy: hypercyanotic episodes follow emotional or painful upset

#### **Duct-dependent pulmonary circulation**

- Commonly presents in first 10–14 days of life
- severely blue, breathless or shocked
- pulmonary atresia
- critical pulmonary valve stenosis
- tricuspid atresia
- severe Fallot's tetralogy
- transposition of the great arteries without septal defect
- single ventricle anatomy

#### **Acute pulmonary outflow obstruction (cyanotic episodes)**

Fallot's tetralogy or other complex congenital cyanotic heart disease

severe pallor

loss of consciousness

convulsions

### Physical examination

- Remember to check femoral pulses
- If coarctation of the aorta suspected: check BP in upper and lower limbs – normal difference <15 mmHg

### Investigations

***If infant cyanosed or in heart failure, discuss urgency of investigations with consultant***

#### **SpO<sub>2</sub>**

- Check pre (right arm) and postductal (lower limbs)
- when breathing air before oxygen given
- after giving 15 L/min oxygen by mask with a reservoir bag for 10 min

#### **Chest X-ray**

- For cardiac conditions, specifically record:
  - cardiac situs (normal or right side of chest)

Please note that clinical key documents are not designed to be printed, but to be viewed on-line. This is to ensure that the correct and most up to date version is being used. If, in exceptional circumstances, you need to print a copy, please note that the information will only be valid for 24 hours

- aortic arch left or right-sided
- bronchial situs (is right main bronchus on the right?)
- cardiac size and configuration
- size of pulmonary vessels and pulmonary vascular markings

### **Electrocardiogram**

See **ECG interpretation** guideline

### **Nitrogen washout in cyanosed babies**

- Monitor SpO<sub>2</sub> in air then in headbox after breathing 100% oxygen for 10 min
- in cyanotic congenital heart disease, PaO<sub>2</sub> will remain below 20 kPa with SpO<sub>2</sub> unchanged
- not as reliable as echocardiogram

### **Echocardiogram**

Locally, if available, or refer to regional **paediatric cardiac centre**

## **IMMEDIATE TREATMENT**

***If infant cyanosed or in heart failure, discuss urgency of referral to local paediatric cardiac surgical centre with consultant***

### **Duct-dependent congenital heart disease**

- Immediate treatment before transfer to **paediatric cardiac centre**:
- open duct with alprostadil (prostaglandin E<sub>1</sub>) or dinoprostone (E<sub>2</sub>): see **Prostaglandin infusion**

### **Acute pulmonary outflow obstruction (cyanotic episodes)**

Immediate treatment before transfer to **paediatric cardiac centre**:

- do not upset child
- give morphine 50–100 microgram/kg IV over 5 min or IM
- provide high concentration face mask oxygen (15 L/min with reservoir bag)
- if Fallot's tetralogy has been diagnosed by echocardiography, discuss use of IV beta-blocker with cardiologist

## **SUBSEQUENT MANAGEMENT**

- On advice of consultant and **paediatric cardiac centre**

## **PROSTAGLANDIN INFUSION**

### **Dosage**

- Ranges from 5–50 nanogram/kg/min (higher doses may be advised by cardiologist)
- Antenatal diagnosis of duct dependent lesion:
  - start at 5 nanogram/kg/min
- Cyanotic baby or with poorly palpable pulses who is otherwise well and non-acidotic:
  - start at 5–15 nanogram/kg/min
- Acidotic or unwell baby with suspected duct dependent lesion:
  - start at 10–20 nanogram/kg/min. If no response within first hour, consider an increase of up to 50 nanogram/kg/min

### **Desired response**

- Suspected left-sided obstruction:
  - aim for palpable pulses, normal pH and normal lactate
- Suspected right-sided obstruction:
  - aim for SpO<sub>2</sub> 75–85% and normal lactate
- Suspected or known transposition of the great arteries (TGA) or hypoplastic left or right heart syndrome with SpO<sub>2</sub> <70% or worsening lactate
  - liaise urgently with cardiology and/or intensive care/retrieval team as rapid assessment and atrial septostomy may be necessary

## Preparations

**Dinoprostone (prostaglandin E<sub>2</sub>) is the recommended prostaglandin\***

Dinoprostone infusion	Other information
<ul style="list-style-type: none"> <li>Standard dinoprostone infusion</li> <li>Make a solution of 500 microgram in 500 mL by adding 0.5 mL of dinoprostone 1 mg in 1 mL to a 500 mL bag of suitable diluent (glucose 5% or 10% or sodium chloride 0.45% and 0.9%)</li> <li>Transfer 50 mL of this solution into a 50 mL Luer lock syringe and label</li> <li>Discard the 500 mL bag immediately into clinical waste – single patient and single dose use only</li> <li>Infusion rate: 0.3 mL/kg/hr = 5 nanogram/kg/min</li> </ul>	<ul style="list-style-type: none"> <li><b>Stability:</b> <ul style="list-style-type: none"> <li>• syringe stable for 24 hr</li> </ul> </li> <li><b>Compatibility:</b> <ul style="list-style-type: none"> <li>• infuse dinoprostone via separate line</li> </ul> </li> <li><b>Flush:</b> <ul style="list-style-type: none"> <li>• sodium chloride 0.9% at same rate as infusion</li> </ul> </li> <li><b>Administration:</b> <ul style="list-style-type: none"> <li>• continuously (short half-life). Ensure 2 working points of IV access at all times</li> <li>• infusions can be given via long line, UVC or peripherally</li> <li>• extravasation can cause necrosis – use central access if available</li> </ul> </li> </ul>

\*If dinoprostone IV not available, use alprostadil (prostaglandin E<sub>1</sub>) IV as alternative (see **BNFc**)

### Oral dinoprostone (see **BNFc**)

- Used temporarily on very rare occasions when IV access is extremely difficult
- Discuss with cardiac centre before using
- Use dinoprostone injection orally
- May not be as effective as prostaglandin IV

### Side effects

#### Common

- Apnoea – tends to occur in first hour after starting prostaglandin or when dose increased. Consider ventilation
- Hypotension – due to systemic vasodilatation. Consider sodium chloride 0.9% 10 mL/kg bolus
- Fever
- Tachycardia
- Hypoglycaemia

#### Uncommon

- Hypothermia
- Bradycardia
- Convulsions
- Cardiac arrest
- Diarrhoea
- Disseminated intravascular coagulation (DIC)
- Gastric outlet obstruction
- Cortical hyperostosis
- Gastric hyperplasia (prolonged use)

### Monitor

- Heart rate
- Blood pressure
- Respiratory rate
- Temperature
- Oxygen saturations
- Blood gases
- Blood glucose and lactate